Tralokinumab
- Product Name
- Tralokinumab
- CAS No.
- 1044515-88-9
- Chemical Name
- Tralokinumab
- Synonyms
- Tralokinumab;CAT-354|||LP 0162;Tralokinumab (anti-IL-13);Research Grade Tralokinumab;Research Grade Tralokinumab(DHE07703)
- CBNumber
- CB68080758
- Formula Weight
- 0
- MOL File
- Mol file
Tralokinumab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Tralokinumab Chemical Properties,Usage,Production
Uses
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis[1][2].
in vivo
Tralokinumab (3 mg/kg; intraperitoneal injection; once every other day; from day 35 to day 63) can inhibit pulmonary fibrosis and reduce epithelial cell apoptosis in a humanized SCID mouse model of pulmonary fibrosis[2].
| Animal Model: | Female C.B-17-scid-beige (C.B-17SCID/bg) mice received single-cell preparations of IPF and normal fibroblasts via tail vein injection[2] |
| Dosage: | 3 mg/kg |
| Administration: | Intraperitoneal injection; once every other day; from day 35 to day 63 |
| Result: | Blocked aberrant lung remodeling, promoted lung repair and restored epithelial integrity. Significantly decreased fibrotic alterations. Reduced serum CC16 (a marker of epithelial injury) and reduced BAL caspase 3 activity. Enhanced the expression of epithelial-associated genes, including E-cadherin and all of the surfactants. |
IC 50
IL-13
References
[1] A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449. DOI:10.1111/bjd.19574
[2] Murray LA, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014 May;50(5):985-94. DOI:10.1165/rcmb.2013-0342OC
Tralokinumab Preparation Products And Raw materials
Raw materials
Preparation Products
Tralokinumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 400-1647117 13681763483
- product02@bidepharm.com
- Country
- China
- ProdList
- 59936
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58